Friday , November 24 2017
Home / Resources / Products / Eylea (aflibercept)

Eylea (aflibercept)

 

FDA Approves Aflibercept for Diabetic Retinopathy in Patients with Diabetic Macular Oedema. The US Food and Drug Administration (FDA) expanded the approved use for aflibercept (Eylea) injection to treat diabetic retinopathy in patients with diabetic macular oedema (DME). Aflibercept is administered by a physician as an injection into the eye once a month for the first 5 injections and then once every 2 months. It is intended to be used along with appropriate interventions to control blood sugar, blood pressure, and cholesterol. The safety and efficacy of aflibercept to treat diabetic retinopathy in patients with DME were evaluated in 679 participants in 2 clinical studies where participants were randomised to receive aflibercept or macular laser photocoagulation. At week 100, participants being treated with aflibercept showed significant improvement in the severity of their diabetic retinopathy, compared with patients who did not receive aflibercept.